Follow
Andrew Pardoll
Andrew Pardoll
Johns Hopkins University school of medicine
Verified email at jhmi.edu
Title
Cited by
Cited by
Year
The blockade of immune checkpoints in cancer immunotherapy
DM Pardoll
Nature reviews cancer 12 (4), 252-264, 2012
152902012
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ...
New England Journal of Medicine 366 (26), 2443-2454, 2012
142602012
PD-1 blockade in tumors with mismatch-repair deficiency
DT Le, JN Uram, H Wang, BR Bartlett, H Kemberling, AD Eyring, ...
New England Journal of Medicine 372 (26), 2509-2520, 2015
100052015
Safety and activity of anti–PD-L1 antibody in patients with advanced cancer
JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ...
New England Journal of Medicine 366 (26), 2455-2465, 2012
90882012
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ...
Science 357 (6349), 409-413, 2017
64402017
STATs in cancer inflammation and immunity: a leading role for STAT3
H Yu, D Pardoll, R Jove
Nature reviews cancer 9 (11), 798-809, 2009
47792009
Immune checkpoint blockade: a common denominator approach to cancer therapy
SL Topalian, CG Drake, DM Pardoll
Cancer cell 27 (4), 450-461, 2015
42662015
Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ...
Journal of clinical oncology 28 (19), 3167-3175, 2010
36702010
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor …
G Dranoff, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose, ...
Proceedings of the National Academy of Sciences 90 (8), 3539-3543, 1993
34351993
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ...
Journal of clinical oncology 32 (10), 1020-1030, 2014
27532014
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
SL Topalian, JM Taube, RA Anders, DM Pardoll
Nature Reviews Cancer 16 (5), 275-287, 2016
26962016
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy
JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ...
Clinical cancer research 20 (19), 5064-5074, 2014
26082014
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ...
Science translational medicine 4 (127), 127ra37-127ra37, 2012
24672012
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
H Yu, M Kortylewski, D Pardoll
Nature reviews immunology 7 (1), 41-51, 2007
21942007
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
20792018
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ...
Cell 162 (5), 974-986, 2015
18682015
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses
S Wu, KJ Rhee, E Albesiano, S Rabizadeh, X Wu, HR Yen, DL Huso, ...
Nature medicine 15 (9), 1016-1022, 2009
18682009
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape
SR Woo, ME Turnis, MV Goldberg, J Bankoti, M Selby, CJ Nirschl, ...
Cancer research 72 (4), 917-927, 2012
18432012
The Central Role of CD4+ T Cells in the Antitumor Immune Response
K Hung, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, ...
The Journal of experimental medicine 188 (12), 2357-2368, 1998
17241998
Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity
SL Topalian, CG Drake, DM Pardoll
Current opinion in immunology 24 (2), 207-212, 2012
17132012
The system can't perform the operation now. Try again later.
Articles 1–20